Latest Content

Phase 3 SUNRISE data show tezepelumab reduced oral corticosteroid use while maintaining asthma control in severe asthma.

Psoriasis may share a tryptophan-driven metabolic pathway behind depression, arthritis, and metabolic syndrome.

Invited commentaries on the CORAL trial praise nalbuphine's potential in IPF cough while raising questions about safety and durability.

The 2026 EHA Congress, convening in Stockholm next week, will bring the global hematology community together for 4 days of science, debate, and discovery.

New review guides hair loss care for transgender and gender-diverse patients, detailing how androgenic alopecia interacts with hormones and key therapies.

CLL’s intrinsic immune dysfunction spans humoral, cellular, and innate defects, persisting even with targeted therapy.

Cancer trauma, drug pricing claims, abortion cost gaps, insurance denials affecting 1 in 5, and food insecurity's economic toll top this week's roundup.

FDA decisions in May 2026 included 5 major oncology approvals, including first-in-class therapies for breast cancer, AML, MCL, and NMIBC.

Late-breaker data from EASL Congress 2026 mark a pivotal moment in chronic hepatitis B research.